Fulcrum Therapeutics (FULC) stock gains as Leerink Partners upgrades the stock, citing a favorable risk-reward setup ahead of a key trial readout. Read more here.

Analysts were effusive about Merus’ new HNSCC data, writing that petosemtamab could “become the standard of care” in the ...

Fintel reports that on May 23, 2025, Leerink Partners upgraded their outlook for Fulcrum Therapeutics (NasdaqGM:FULC) from ...

The advisory committee meeting comes days after the FDA unveiled a new risk-based approval framework for COVID-19 vaccines.

While some analysts questioned why Medtronic would leave a fast-growing market, others backed the company’s plan to focus on ...

A rough earnings report raised troubling questions about UHG’s future, and so did the resignation of CEO Andrew Witty.

While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the ...

All of the shares, pre-funded warrants and accompanying common stock warrants in the offering are being sold by Aura. The gross proceeds from the offering to Aura are expected to be $75.0 million, ...

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver disease franchise.

Fintel reports that on May 13, 2025, Leerink Partners downgraded their outlook for Johnson & Johnson (NYSE:JNJ) from ...

Live Updates Live Coverage Updates appear automatically as they are published. Moving On Up 10:09 am After opening barely ...

Johnson & Johnson (NYSE:JNJ) stock and Halozyme (HALO) stock were downgraded at Leerink Partners on earlier than expected price controls for products. Read more here.